Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer

WEDNESDAY, Dec. 18, 2019 -- Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news